THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
105.02%
Total 13F principal
$231,305,180
Principal change
-$8,446,826
Total reported market value
$244,594,124
Number of holders
23
Value change
-$8,478,868
Number of buys
9
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q2 2019

As of 30 Jun 2019, THERAVANCE INC - CORPORATE OBLIG was held by 23 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $231,305,180 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, Antara Capital LP, ADVENT CAPITAL MANAGEMENT /DE/, CNH PARTNERS LLC, LAZARD ASSET MANAGEMENT LLC, CALAMOS ADVISORS LLC, AMERIPRISE FINANCIAL INC, NEW YORK STATE COMMON RETIREMENT FUND, SSI INVESTMENT MANAGEMENT LLC, and FMR LLC. This page lists 23 institutional bondholders reporting positions for the Q2 2019 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.